Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Kato

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Bioorganic & Medicinal Chemistry|April 30, 2021
Discovery of a potent and selective Axl inhibitor in preclinical modelSatoshi Inoue, Yoshinobu Yamane, Shuntaro Tsukamoto, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 2021
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitorsSatoshi Inoue, Yoshinobu Yamane, Shuntaro Tsukamoto, et al.
Clinical and Translational Gastroenterology|March 29, 2022
Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating TherapiesBrigid S Boland, Benjamin Goodwin, Zeli Zhang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 17, 2011
Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotypeMireille H Lahoud, Fatma Ahmet, Susie Kitsoulis, et al.
The Journal of Experimental Medicine|October 22, 2021
Sphingosine 1-phosphate receptor 5 (S1PR5) regulates the peripheral retention of tissue-resident lymphocytesMaximilien Evrard, Erica Wynne-Jones, Changwei Peng, et al.
Molecular Cancer Therapeutics|October 24, 2022
ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic DrugsShuntaro Tsukamoto, Naoko Hata Sugi, Kyoko Nishibata, et al.
Biorxiv : the Preprint Server for Biology|January 14, 2021
Immunological memory to SARS-CoV-2 assessed for up to eight months after infectionJennifer M Dan, Jose Mateus, Yu Kato, et al.
Science (New York, N.Y.)|January 7, 2021
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infectionJennifer M Dan, Jose Mateus, Yu Kato, et al.
Cell|October 4, 2020
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease SeverityCarolyn Rydyznski Moderbacher, Sydney I Ramirez, Jennifer M Dan, et al.
Nature Medicine|May 15, 2020
Author Correction: A Engineered immunogen binding to alum adjuvant enhances humoral immunityTyson J Moyer, Yu Kato, Wuhbet Abraham, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Bioorganic & Medicinal Chemistry|April 30, 2021
Discovery of a potent and selective Axl inhibitor in preclinical modelSatoshi Inoue, Yoshinobu Yamane, Shuntaro Tsukamoto, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 2021
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitorsSatoshi Inoue, Yoshinobu Yamane, Shuntaro Tsukamoto, et al.
Clinical and Translational Gastroenterology|March 29, 2022
Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating TherapiesBrigid S Boland, Benjamin Goodwin, Zeli Zhang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 17, 2011
Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotypeMireille H Lahoud, Fatma Ahmet, Susie Kitsoulis, et al.
The Journal of Experimental Medicine|October 22, 2021
Sphingosine 1-phosphate receptor 5 (S1PR5) regulates the peripheral retention of tissue-resident lymphocytesMaximilien Evrard, Erica Wynne-Jones, Changwei Peng, et al.
Molecular Cancer Therapeutics|October 24, 2022
ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic DrugsShuntaro Tsukamoto, Naoko Hata Sugi, Kyoko Nishibata, et al.
Biorxiv : the Preprint Server for Biology|January 14, 2021
Immunological memory to SARS-CoV-2 assessed for up to eight months after infectionJennifer M Dan, Jose Mateus, Yu Kato, et al.
Science (New York, N.Y.)|January 7, 2021
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infectionJennifer M Dan, Jose Mateus, Yu Kato, et al.
Cell|October 4, 2020
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease SeverityCarolyn Rydyznski Moderbacher, Sydney I Ramirez, Jennifer M Dan, et al.
Nature Medicine|May 15, 2020
Author Correction: A Engineered immunogen binding to alum adjuvant enhances humoral immunityTyson J Moyer, Yu Kato, Wuhbet Abraham, et al.
Pageof 10